Demand’s elastic, not fantastic
19 April 2016

Illumina rode the rapidly falling cost of genetic sequencing to a $26 bln valuation as demand bloomed. But a warning of slower growth evaporated almost 25 pct off the stock. Heady multiples only survive if ever cheaper overheads foster ever more uses for a company’s products.